MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.

Phase 3CARTISTEMPositive

AI Analysis

Summary

MEDIPOST secured FDA agreement to conduct a single pivotal Phase 3 study for CARTISTEM in the U.S. with a confirmatory evidence BLA filing strategy, marking a significant regulatory milestone for the cell therapy program.

Clinical Trial Data

Phase

Phase 3

Outcome Details

FDA agreed to single pivotal Phase 3 study with confirmatory evidence BLA filing strategy

Importance:7/10

Sentiment:

0.70

cell therapyFDA agreementPhase 3BLA filing strategypivotal study

Related Companies

$INBP

Read the original article

Published by PR Newswire Biotech on June 4, 2026 3:36 AM

Read Original